StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) company profile

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.24−0.08 (-1.09%)

Close on Nov 17, 2026Market cap $477.94MP/E –Yield –

About Regenxbio

Biological Products, (No Diagnostic Substances), SIC 2836

REGENXBIO Inc. is a clinical-stage biotechnology company that focuses on the development and commercialization of gene therapies. The company utilizes its proprietary NAV Technology Platform to deliver genetic medicines for severe conditions. Its pipeline includes surabgene lomparvovec, RGX-121, and RGX-111, which are evaluated across clinical studies such as AAVIATE, ALTITUDE, and ATMOSPHERE. REGENXBIO provides development services, licensing rights, and technology access to partners. Its customers and collaborators primarily consist of global pharmaceutical and biotechnology companies, such as AbbVie and Nippon Shinyaku, as well as research institutions.

The company operates within the United States and maintains business relationships across international regions, including Ireland, Japan, Germany, and the United Arab Emirates. Its facilities include sites along Medical Center Drive in Maryland and leased space in New York. REGENXBIO is headquartered in Rockville, Maryland.

Summary of the business section of Regenxbio's latest annual report, written by StockData.

Company profile

Company

Legal name
REGENXBIO Inc.
Headquarters
Rockville, MD
Address
9804 Medical Center Drive 20850
Phone
(240) 552-8181
Employees
371, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Washington, District of Columbia

Stock & identifiers

Ticker
RGNX
Exchange
Nasdaq
IPO date
Sep 17, 2015
Shares outstanding
66M, Jul 31, 2026
Public float
$385.01M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1590877
CUSIP
75901B107
ISIN
US75901B1070
FIGI
BBG007Z9V591
Share class FIGI
BBG007Z9V5C7
LEI
549300EOES47LATSET33
EIN
47-1851754

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Curran SimpsonChief Executive Officer, Director338,053
Craig MalzahnChief Technology Officer109,737
Mitchell ChanChief Financial Officer147,120
Patrick J. ChristmasChief Strategy & Legal Officer240,690
Steve PakolaChief Medical Officer240,263
Olivier DanosChief Scientific Officer226,348
Gregory Austin CiongoliDirector118,035
Daniel TasseDirector28,861
George V. MigauskyDirector28,861
Jean BennettDirector28,861
Jennifer ZacharyDirector31,871
Argeris N. KarabelasDirector28,861
David C. StumpDirector28,861
Kenneth T. MillsDirector495,925
Allan M. FoxDirector2,911,327
Alexandra GlucksmannDirector28,861

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.20M$9.33M$1.92M$63–
FY2024
Curran Simpson
$4.78M$1.87M$2.76M$34–
FY2024
Kenneth TMills
$5.51M-$253.33K$2.76M$34–
FY2023$5.92M$3.05M$2.96M$79–
FY2022$5.75M$1.41M$1.99M$55$114
FY2021$8.62M$2.65M$3.21M$80$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Curran Simpson
President and Chief Executive Officer
$665.51K–$777.45K$2.35M$387.33K$20.13K$4.20M-12%
Stephen Pakola, M.D.
EVP, Chief Medical Officer
$543.99K–$505.34K$509.23K$220.86K$20.13K$1.80M-33%
Patrick J. Christmas
EVP, Chief Strategy and Legal Officer
$520.90K$200.00K–$1.10M$203.67K$20.13K$2.04M-25%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 17, 2015
Offer price
$22.00
Securities offered
6,300,000
Gross proceeds
$138.60M
Exchange
Nasdaq
First trading day
Sep 17, 2015
First-day close
$30.45+38.4%
Lock-up ends (est.)
Mar 15, 2016

“The initial public offering price is $22.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 27, 2026, we employed 371 full-time employees, of which 296 were engaged in research and development activities, including preclinical, clinical and manufacturing related functions, and 75 were engaged in general administrative activities, including commercial, corporate development, finance, legal, human resources, information technology, fac”

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 17, 2015IPOInitial public offering priced (424B4 prospectus)
Sep 9, 2015ListingRegistration of securities on an exchange (Form 8-A)
Nov 7, 2013Name changeName changed from ReGenX Biosciences, LLC to REGENXBIO Inc.

See a number that looks wrong?